Jennifer Richer
Concepts (448)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 16 | 2025 | 203 | 6.470 |
Why?
| | Receptors, Androgen | 13 | 2023 | 149 | 4.970 |
Why?
| | Breast Neoplasms | 45 | 2025 | 2274 | 3.800 |
Why?
| | MicroRNAs | 17 | 2018 | 678 | 3.650 |
Why?
| | Androgen Receptor Antagonists | 8 | 2021 | 35 | 2.370 |
Why?
| | Anoikis | 7 | 2021 | 31 | 2.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 35 | 2025 | 1388 | 2.140 |
Why?
| | Tryptophan | 4 | 2024 | 183 | 1.890 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3404 | 1.820 |
Why?
| | Estrogen Receptor alpha | 6 | 2022 | 144 | 1.800 |
Why?
| | Receptors, Progesterone | 24 | 2016 | 349 | 1.800 |
Why?
| | Phenylthiohydantoin | 6 | 2017 | 42 | 1.690 |
Why?
| | Tryptophan Oxygenase | 5 | 2024 | 34 | 1.630 |
Why?
| | Receptors, Estrogen | 14 | 2020 | 435 | 1.330 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 576 | 1.130 |
Why?
| | Neoplasm Invasiveness | 4 | 2024 | 498 | 0.970 |
Why?
| | Progesterone | 16 | 2014 | 256 | 0.970 |
Why?
| | Progestins | 6 | 2014 | 80 | 0.930 |
Why?
| | Tamoxifen | 10 | 2016 | 201 | 0.920 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 57 | 0.880 |
Why?
| | Ribonuclease III | 2 | 2016 | 40 | 0.830 |
Why?
| | Neoplastic Stem Cells | 3 | 2017 | 399 | 0.800 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 75 | 0.800 |
Why?
| | Epithelial Cells | 3 | 2022 | 1100 | 0.800 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2018 | 211 | 0.780 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2020 | 796 | 0.770 |
Why?
| | Adipokines | 2 | 2024 | 47 | 0.770 |
Why?
| | Biomarkers, Tumor | 7 | 2021 | 1235 | 0.770 |
Why?
| | Receptor, ErbB-2 | 4 | 2017 | 342 | 0.770 |
Why?
| | Cell Proliferation | 14 | 2021 | 2472 | 0.750 |
Why?
| | Kallikreins | 1 | 2021 | 28 | 0.730 |
Why?
| | Gene Expression Profiling | 11 | 2018 | 1755 | 0.700 |
Why?
| | Prostate-Specific Antigen | 1 | 2021 | 167 | 0.680 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 150 | 0.670 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 172 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 1052 | 0.660 |
Why?
| | Endometrial Neoplasms | 6 | 2011 | 199 | 0.660 |
Why?
| | Trophoblasts | 1 | 2022 | 199 | 0.650 |
Why?
| | Immunohistochemistry | 8 | 2017 | 1718 | 0.650 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 165 | 0.640 |
Why?
| | Transcription Factors | 13 | 2023 | 1709 | 0.640 |
Why?
| | Cell Movement | 9 | 2020 | 971 | 0.640 |
Why?
| | Pulmonary Alveoli | 1 | 2022 | 405 | 0.630 |
Why?
| | Androgen Antagonists | 3 | 2017 | 93 | 0.630 |
Why?
| | Mammary Glands, Animal | 4 | 2022 | 130 | 0.620 |
Why?
| | Female | 64 | 2025 | 73648 | 0.610 |
Why?
| | Alternative Splicing | 2 | 2018 | 226 | 0.610 |
Why?
| | Homeodomain Proteins | 5 | 2014 | 506 | 0.610 |
Why?
| | Repressor Proteins | 6 | 2018 | 423 | 0.600 |
Why?
| | Cell Cycle | 4 | 2021 | 600 | 0.590 |
Why?
| | Humans | 92 | 2025 | 138102 | 0.580 |
Why?
| | Up-Regulation | 7 | 2020 | 844 | 0.580 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 55 | 0.570 |
Why?
| | Mammary Neoplasms, Experimental | 3 | 2017 | 68 | 0.560 |
Why?
| | Mice | 24 | 2025 | 17769 | 0.530 |
Why?
| | Animals | 39 | 2025 | 37151 | 0.530 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2021 | 865 | 0.520 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 50 | 0.520 |
Why?
| | Benzamides | 6 | 2017 | 209 | 0.510 |
Why?
| | Nitriles | 6 | 2017 | 176 | 0.510 |
Why?
| | Lactation | 2 | 2022 | 181 | 0.510 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 139 | 0.510 |
Why?
| | Lipogenesis | 1 | 2016 | 61 | 0.500 |
Why?
| | Antibody Specificity | 1 | 2016 | 187 | 0.490 |
Why?
| | Paclitaxel | 3 | 2017 | 237 | 0.490 |
Why?
| | Receptor, trkB | 2 | 2012 | 33 | 0.470 |
Why?
| | Antineoplastic Agents | 6 | 2018 | 2125 | 0.470 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2015 | 55 | 0.460 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.450 |
Why?
| | Apoptosis | 11 | 2020 | 2555 | 0.440 |
Why?
| | Kynurenine | 4 | 2024 | 114 | 0.430 |
Why?
| | RNA Interference | 3 | 2015 | 468 | 0.430 |
Why?
| | Antibodies | 1 | 2016 | 406 | 0.430 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 414 | 0.420 |
Why?
| | Receptors, Steroid | 2 | 2010 | 46 | 0.420 |
Why?
| | Metformin | 2 | 2014 | 337 | 0.410 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 668 | 0.410 |
Why?
| | Gene Expression Regulation | 8 | 2016 | 2586 | 0.400 |
Why?
| | Signal Transduction | 18 | 2025 | 5068 | 0.390 |
Why?
| | Chromatin | 1 | 2016 | 517 | 0.380 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 912 | 0.370 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 407 | 0.370 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 66 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1702 | 0.370 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 55 | 0.360 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2024 | 78 | 0.360 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2020 | 165 | 0.360 |
Why?
| | Disease Progression | 6 | 2018 | 2730 | 0.350 |
Why?
| | Endometrium | 2 | 2008 | 59 | 0.340 |
Why?
| | NF-kappa B | 3 | 2025 | 679 | 0.340 |
Why?
| | Transcriptional Activation | 5 | 2017 | 373 | 0.330 |
Why?
| | Mice, SCID | 4 | 2020 | 368 | 0.330 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 329 | 0.310 |
Why?
| | Tubulin Modulators | 1 | 2009 | 10 | 0.310 |
Why?
| | Cells | 1 | 2009 | 25 | 0.300 |
Why?
| | 3' Untranslated Regions | 4 | 2014 | 145 | 0.300 |
Why?
| | Estradiol | 6 | 2016 | 525 | 0.300 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 24 | 0.300 |
Why?
| | Killer Cells, Natural | 2 | 2025 | 451 | 0.300 |
Why?
| | Cadherins | 4 | 2012 | 201 | 0.300 |
Why?
| | Uterine Neoplasms | 2 | 2008 | 114 | 0.290 |
Why?
| | Neoplasms | 5 | 2022 | 2712 | 0.280 |
Why?
| | Dirofilaria immitis | 3 | 2010 | 3 | 0.280 |
Why?
| | Mice, Nude | 5 | 2017 | 690 | 0.280 |
Why?
| | Feedback, Physiological | 2 | 2021 | 79 | 0.270 |
Why?
| | Trastuzumab | 2 | 2017 | 96 | 0.260 |
Why?
| | Mutation | 7 | 2022 | 3994 | 0.260 |
Why?
| | Cell Nucleus | 5 | 2017 | 612 | 0.260 |
Why?
| | Transfection | 5 | 2012 | 938 | 0.260 |
Why?
| | MCF-7 Cells | 3 | 2016 | 123 | 0.250 |
Why?
| | Microtubules | 1 | 2009 | 280 | 0.250 |
Why?
| | Epidermal Growth Factor | 4 | 2005 | 176 | 0.250 |
Why?
| | Genetic Diseases, Inborn | 2 | 2017 | 44 | 0.250 |
Why?
| | Fibrillin-1 | 1 | 2024 | 6 | 0.230 |
Why?
| | Mice, Inbred NOD | 3 | 2020 | 597 | 0.230 |
Why?
| | Anilides | 2 | 2016 | 72 | 0.230 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 116 | 0.230 |
Why?
| | Marfan Syndrome | 1 | 2024 | 41 | 0.220 |
Why?
| | Down-Regulation | 6 | 2016 | 635 | 0.220 |
Why?
| | Cell Differentiation | 1 | 2012 | 1999 | 0.220 |
Why?
| | Gene Expression | 4 | 2020 | 1487 | 0.220 |
Why?
| | Microarray Analysis | 2 | 2016 | 116 | 0.220 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 8 | 0.210 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 407 | 0.210 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 758 | 0.200 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2571 | 0.200 |
Why?
| | Tumor Cells, Cultured | 11 | 2020 | 946 | 0.190 |
Why?
| | Milk Proteins | 2 | 1999 | 34 | 0.190 |
Why?
| | Mammary Glands, Human | 2 | 2014 | 65 | 0.190 |
Why?
| | Genetic Variation | 2 | 2024 | 1002 | 0.180 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 648 | 0.180 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 94 | 0.180 |
Why?
| | Epithelium | 1 | 2022 | 316 | 0.180 |
Why?
| | Estrogens | 3 | 2020 | 369 | 0.180 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2022 | 79 | 0.180 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2166 | 0.180 |
Why?
| | Promoter Regions, Genetic | 6 | 2014 | 1237 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 114 | 0.170 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 429 | 0.170 |
Why?
| | DNA-Binding Proteins | 6 | 2018 | 1477 | 0.170 |
Why?
| | Semaphorins | 1 | 2020 | 34 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 61 | 0.160 |
Why?
| | Epoxy Compounds | 1 | 2020 | 31 | 0.160 |
Why?
| | Androgens | 1 | 2021 | 186 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2022 | 366 | 0.160 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 329 | 0.160 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 45 | 0.160 |
Why?
| | Respiratory Mucosa | 1 | 2022 | 320 | 0.160 |
Why?
| | Transcription, Genetic | 9 | 2012 | 1455 | 0.160 |
Why?
| | Neoplasm Metastasis | 3 | 2025 | 664 | 0.160 |
Why?
| | STAT5 Transcription Factor | 3 | 2014 | 57 | 0.160 |
Why?
| | RNA, Messenger | 7 | 2011 | 2799 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 373 | 0.150 |
Why?
| | Pregnancy | 3 | 2022 | 6789 | 0.150 |
Why?
| | Prolactin | 1 | 1998 | 95 | 0.150 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 621 | 0.150 |
Why?
| | Gene Amplification | 1 | 2018 | 103 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 703 | 0.140 |
Why?
| | Immunoblotting | 3 | 2010 | 306 | 0.140 |
Why?
| | Endometrial Hyperplasia | 2 | 2008 | 8 | 0.140 |
Why?
| | Binding Sites | 5 | 2016 | 1317 | 0.140 |
Why?
| | Antigens, CD | 1 | 2020 | 530 | 0.140 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2017 | 45 | 0.130 |
Why?
| | Cluster Analysis | 4 | 2008 | 515 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 88 | 0.130 |
Why?
| | Dihydrotestosterone | 1 | 2017 | 44 | 0.130 |
Why?
| | Histone Acetyltransferases | 3 | 2006 | 61 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 270 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 446 | 0.130 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 250 | 0.130 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.130 |
Why?
| | Heterografts | 1 | 2017 | 135 | 0.130 |
Why?
| | Cyclohexanes | 1 | 2016 | 21 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 206 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 2 | 2014 | 324 | 0.120 |
Why?
| | Enzyme Inhibitors | 3 | 2024 | 847 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 216 | 0.120 |
Why?
| | Trans-Activators | 4 | 2006 | 395 | 0.120 |
Why?
| | Hyaluronan Receptors | 2 | 2014 | 103 | 0.120 |
Why?
| | Placenta | 1 | 2022 | 752 | 0.120 |
Why?
| | Ovary | 1 | 2017 | 223 | 0.120 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 195 | 0.120 |
Why?
| | Genes | 1 | 2015 | 229 | 0.120 |
Why?
| | Genetic Association Studies | 1 | 2017 | 373 | 0.110 |
Why?
| | Phosphoproteins | 2 | 2008 | 340 | 0.110 |
Why?
| | Hormones | 1 | 2015 | 145 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 828 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 357 | 0.110 |
Why?
| | Exome | 1 | 2015 | 234 | 0.110 |
Why?
| | Tosyl Compounds | 1 | 2014 | 16 | 0.110 |
Why?
| | Genes, Reporter | 2 | 2012 | 272 | 0.110 |
Why?
| | Ligands | 6 | 2023 | 666 | 0.100 |
Why?
| | Protein Transport | 1 | 2015 | 441 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2016 | 730 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 163 | 0.100 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 100 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 2374 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 318 | 0.100 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 1993 | 49 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 98 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2016 | 4160 | 0.100 |
Why?
| | Neurotrophin 3 | 1 | 2012 | 10 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4309 | 0.100 |
Why?
| | Cell Adhesion | 2 | 2012 | 465 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1032 | 0.100 |
Why?
| | Ketones | 1 | 1993 | 47 | 0.100 |
Why?
| | Autocrine Communication | 1 | 2012 | 41 | 0.100 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2015 | 369 | 0.100 |
Why?
| | Middle Aged | 7 | 2024 | 33509 | 0.100 |
Why?
| | Metalloendopeptidases | 1 | 1992 | 59 | 0.100 |
Why?
| | Aromatase Inhibitors | 2 | 2014 | 58 | 0.100 |
Why?
| | Cysteine Endopeptidases | 1 | 1992 | 73 | 0.100 |
Why?
| | Family | 1 | 2017 | 673 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2012 | 136 | 0.090 |
Why?
| | Disease-Free Survival | 1 | 2014 | 669 | 0.090 |
Why?
| | Nuclear Proteins | 5 | 2000 | 709 | 0.090 |
Why?
| | Gene Silencing | 2 | 2014 | 197 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 149 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2023 | 738 | 0.090 |
Why?
| | Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 6 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 5769 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 306 | 0.090 |
Why?
| | Receptors, Leptin | 1 | 2011 | 25 | 0.090 |
Why?
| | Tissue Array Analysis | 2 | 2008 | 51 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 145 | 0.090 |
Why?
| | GTPase-Activating Proteins | 1 | 2011 | 83 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2029 | 0.080 |
Why?
| | Protein Biosynthesis | 2 | 2012 | 433 | 0.080 |
Why?
| | Fibronectins | 1 | 2011 | 132 | 0.080 |
Why?
| | Microfilament Proteins | 1 | 2011 | 133 | 0.080 |
Why?
| | Cell Transdifferentiation | 1 | 2010 | 32 | 0.080 |
Why?
| | HeLa Cells | 5 | 2006 | 635 | 0.080 |
Why?
| | Retinoid X Receptors | 1 | 2010 | 37 | 0.080 |
Why?
| | Cyclins | 3 | 1999 | 92 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 348 | 0.080 |
Why?
| | DNA, Complementary | 4 | 2008 | 275 | 0.080 |
Why?
| | Breast | 2 | 2022 | 157 | 0.080 |
Why?
| | Protein Isoforms | 4 | 2006 | 392 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 979 | 0.080 |
Why?
| | Lung | 1 | 2022 | 4065 | 0.080 |
Why?
| | Inflammation | 1 | 2020 | 2847 | 0.080 |
Why?
| | Prognosis | 3 | 2024 | 3982 | 0.080 |
Why?
| | Cell Line, Transformed | 1 | 2009 | 145 | 0.080 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 206 | 0.070 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1033 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3301 | 0.070 |
Why?
| | Aged | 5 | 2024 | 23995 | 0.070 |
Why?
| | Drug Interactions | 1 | 2009 | 406 | 0.070 |
Why?
| | Leiomyoma | 1 | 2008 | 79 | 0.070 |
Why?
| | Hysterectomy | 1 | 2008 | 133 | 0.070 |
Why?
| | Glycoproteins | 2 | 2024 | 357 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2024 | 786 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 64 | 0.060 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2925 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 598 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1912 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 27 | 0.060 |
Why?
| | Canada | 2 | 2017 | 409 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2006 | 166 | 0.060 |
Why?
| | Thromboplastin | 1 | 2004 | 73 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1301 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1371 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 121 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2024 | 58 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3037 | 0.050 |
Why?
| | Protein Binding | 4 | 2010 | 2232 | 0.050 |
Why?
| | Ovariectomy | 2 | 2017 | 155 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 306 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 461 | 0.050 |
Why?
| | Postmenopause | 3 | 2017 | 370 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2025 | 228 | 0.050 |
Why?
| | Amino Acid Sequence | 4 | 2010 | 2159 | 0.050 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 30 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 419 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2005 | 609 | 0.050 |
Why?
| | Immune Evasion | 1 | 2022 | 58 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 216 | 0.050 |
Why?
| | Larva | 2 | 1993 | 235 | 0.050 |
Why?
| | Biology | 1 | 2022 | 91 | 0.050 |
Why?
| | Promegestone | 4 | 2005 | 33 | 0.050 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 175 | 0.040 |
Why?
| | Consensus | 1 | 2024 | 676 | 0.040 |
Why?
| | Adult | 4 | 2016 | 38063 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 1002 | 0.040 |
Why?
| | Mifepristone | 2 | 2000 | 63 | 0.040 |
Why?
| | Drug Resistance | 2 | 2000 | 145 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 552 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 568 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 287 | 0.040 |
Why?
| | Zinc | 1 | 2024 | 301 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 10832 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2020 | 76 | 0.040 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.040 |
Why?
| | Exons | 2 | 1999 | 353 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 98 | 0.040 |
Why?
| | Postpartum Period | 1 | 2022 | 343 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 13329 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2006 | 880 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 807 | 0.040 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.040 |
Why?
| | Immunological Synapses | 1 | 2018 | 17 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2008 | 7638 | 0.040 |
Why?
| | p300-CBP Transcription Factors | 1 | 2018 | 27 | 0.040 |
Why?
| | DNA Helicases | 1 | 2000 | 140 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 71 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 140 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1998 | 185 | 0.040 |
Why?
| | Drug Synergism | 1 | 1998 | 369 | 0.030 |
Why?
| | Oxygenases | 1 | 1997 | 13 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 44 | 0.030 |
Why?
| | Male | 3 | 2021 | 67984 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 363 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 401 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1234 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1998 | 315 | 0.030 |
Why?
| | Consanguinity | 1 | 2017 | 49 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 203 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2005 | 1311 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 92 | 0.030 |
Why?
| | Carcinogens | 1 | 1997 | 126 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 276 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 159 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1999 | 447 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2010 | 360 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1075 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 401 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1544 | 0.030 |
Why?
| | Siblings | 1 | 2017 | 216 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 511 | 0.030 |
Why?
| | Histones | 2 | 2014 | 636 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 441 | 0.030 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 15 | 0.030 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 25 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1260 | 0.030 |
Why?
| | Base Sequence | 3 | 2008 | 2180 | 0.030 |
Why?
| | Keratin-5 | 1 | 2014 | 49 | 0.030 |
Why?
| | Nuclear Receptor Coactivator 1 | 2 | 2006 | 11 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 458 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 739 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 403 | 0.030 |
Why?
| | Dipeptides | 1 | 1993 | 50 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 508 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2017 | 645 | 0.020 |
Why?
| | Chromatography | 1 | 1992 | 23 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1993 | 435 | 0.020 |
Why?
| | Elastin | 1 | 1992 | 78 | 0.020 |
Why?
| | Hydrolysis | 1 | 1992 | 194 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 1992 | 109 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 541 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1876 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5144 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 201 | 0.020 |
Why?
| | Oligopeptides | 1 | 1992 | 270 | 0.020 |
Why?
| | Cell Size | 1 | 2010 | 90 | 0.020 |
Why?
| | Cell Dedifferentiation | 1 | 2010 | 31 | 0.020 |
Why?
| | COS Cells | 2 | 2003 | 183 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2010 | 21 | 0.020 |
Why?
| | Collagen | 1 | 1992 | 454 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2010 | 146 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 85 | 0.020 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.020 |
Why?
| | DNA Methylation | 1 | 2014 | 641 | 0.020 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5564 | 0.020 |
Why?
| | Phosphorylation | 2 | 2005 | 1760 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3158 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 80 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 1992 | 535 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2022 | 0.020 |
Why?
| | Cell Division | 2 | 2000 | 790 | 0.020 |
Why?
| | Myometrium | 1 | 2008 | 39 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 158 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 77 | 0.020 |
Why?
| | United States | 1 | 2025 | 15028 | 0.020 |
Why?
| | Trypan Blue | 1 | 2006 | 6 | 0.020 |
Why?
| | Comet Assay | 1 | 2006 | 16 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 60 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2006 | 73 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 80 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2006 | 155 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2006 | 103 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4111 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 2 | 2000 | 662 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2006 | 224 | 0.020 |
Why?
| | Androstenes | 1 | 2005 | 18 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2006 | 157 | 0.010 |
Why?
| | Caspase 3 | 1 | 2006 | 249 | 0.010 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2005 | 36 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2005 | 36 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2006 | 160 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 373 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 151 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 231 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 110 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 328 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 487 | 0.010 |
Why?
| | DNA Damage | 1 | 2006 | 422 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 864 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 626 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 322 | 0.010 |
Why?
| | Progesterone Congeners | 1 | 2002 | 16 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 393 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 182 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11142 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 212 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 197 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1130 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 359 | 0.010 |
Why?
| | Ku Autoantigen | 1 | 2000 | 10 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 17 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2000 | 102 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1349 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 73 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1419 | 0.010 |
Why?
| | Methionine | 1 | 2000 | 163 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2003 | 691 | 0.010 |
Why?
| | Growth Substances | 1 | 1999 | 148 | 0.010 |
Why?
| | Estrogen Receptor beta | 1 | 1999 | 40 | 0.010 |
Why?
| | Cricetinae | 1 | 1999 | 296 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2017 | 15750 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1998 | 39 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 55 | 0.010 |
Why?
| | RNA | 1 | 2005 | 926 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 131 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 160 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 24 | 0.010 |
Why?
| | Estrogen Antagonists | 1 | 1998 | 45 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 516 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 149 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 183 | 0.010 |
Why?
| | Isomerism | 1 | 1997 | 55 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 279 | 0.010 |
Why?
| | Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 391 | 0.010 |
Why?
| | Yeasts | 1 | 1997 | 53 | 0.010 |
Why?
| | Autoantigens | 1 | 2000 | 423 | 0.010 |
Why?
| | Blotting, Western | 1 | 1998 | 1223 | 0.010 |
Why?
| | Child | 1 | 2015 | 21990 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1049 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6845 | 0.010 |
Why?
| | Cell Line | 1 | 1998 | 2865 | 0.010 |
Why?
| | Models, Biological | 1 | 1998 | 1784 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 2079 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|